Non-palpable breast carcinomas: Correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression

2006 ◽  
Vol 244 (1) ◽  
pp. 34-41 ◽  
Author(s):  
Filitsa A. Badra ◽  
Michalis V. Karamouzis ◽  
Panagiota Ravazoula ◽  
Eleni Likaki-Karatza ◽  
Evagelos Tzorakoleftherakis ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Breast Carcinomas ◽  
Epidermal Growth ◽  
Palpable Breast ◽  
Egfr Family

scholarly journals Differential effects of epidermal growth factor receptor inhibitors in a single patient with neuropathic pain

2021 ◽  
Vol 14 (3) ◽  
pp. e239385
Author(s):  
Marte Grønlie Cameron ◽  
Christian Kersten
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Neuropathic Pain ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Differential Effects ◽  
Pain Scores ◽  
Medical Need ◽  
Epidermal Growth ◽  
Egfr Family

Neuropathic pain (NP) represents an unmet medical need, where analgesic responses to different epidermal growth factor receptor inhibitors (EGFR-Is) have been described. The human EGFR family of receptors consists of four members (human epidermal growth factor receptor, HER 1–4), signalling via different homodimer and heterodimer combinations. A 52-year-old man was treated with the EGFR-I cetuximab in a trial of severe NP. Pain scores decreased dramatically after blinded cetuximab, but not after placebo. On pain recurrence after the trial, he was prescribed the oral EGFR-Is erlotinib, gefitinib, and lapatinib without relief. However, treatment with the pan-HER-inhibitor afatinib was effective. After 4 years on afatinib, pain control remains excellent with manageable side effects. This is the first reported observation of differential effects of EGFR-Is on NP in the same patient and the first report describing NP relief with afatinib. Further understanding of the underlying pathophysiology could lead to development of EGFR-Is specifically targeting NP.

Prognostic value of epidermal growth factor receptor (EGFR) family members in breast cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e21079-e21079
Author(s):  
T. Badovinac Crnjevic ◽  
J. Jakic-Razumovic ◽  
D. Vrbanec ◽  
A. Juretic ◽  
S. Plestina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Prognostic Value ◽  
Family Members ◽  
Growth Factor Receptor ◽  
Epidermal Growth ◽  
Egfr Family

A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy

2014 ◽  
Vol 42 (4) ◽  
pp. 831-836 ◽  
Author(s):  
Jeroen Claus ◽  
Gargi Patel ◽  
Tony Ng ◽  
Peter J. Parker
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Therapeutic Strategy ◽  
Acquired Resistance ◽  
Growth Factor Receptor ◽  
Targeted Therapeutics ◽  
Epidermal Growth ◽  
Egfr Family ◽  
Receptor Family

Specific inhibition of members of the EGFR (epidermal growth factor receptor) family, particularly EGFR and HER2 (human epidermal growth factor receptor 2), are an important therapeutic strategy in many human cancers. Compared with classical chemotherapy, these targeted therapeutics are very specific and initially effective, but acquired resistance against these targeted therapies is a recurring threat. A growing body of recent work has highlighted a pseudokinase in the EGFR family, HER3, and its ligand, NRG (neuregulin β1), to be of importance in models of resistant cancers, as well as in patients. In the present article, we describe some of the roles in which HER3 can mediate acquired resistance and discuss the current efforts to target HER3 itself in cancer.

Sign in / Sign up

Export Citation Format

Share Document